FeesSafety
Pluang+

Morpho Midnight hits $100M deposits, showing fixed-rate DeFi lending demand.

Protocol Fundamentals
23 Oct 2026
Crypto Briefing
View Source
Bullish
Morpho Midnight hits $100M deposits, showing fixed-rate DeFi lending demand.

Morpho Midnight, a fixed-rate lending protocol launched in July 2026, has surpassed $100 million in deposits within three months. It offers borrowers predictable fixed rates through an innovative system where lenders post their own terms, and capital only locks when matched. This approach differs from traditional variable-rate lending and aims to attract users seeking stability. Coinbase and Robinhood support the protocol, signaling growing interest in fixed-rate DeFi loans, though total value locked is currently lower than deposit figures, highlighting a unique liquidity design.

Morpho Midnight's milestone of surpassing $100 million in deposits provides context for readers interested in fixed-rate DeFi lending. For readers following the broader cryptocurrency market, here is Pluang's market snapshot as of Oct 23, 2026 19:01 WIB: Among 50 major cryptocurrencies priced on Pluang, 26 rose and 23 fell today. Notable movers include ONE (Harmony) at Rp26 with a 1-day change of +2.48% and Pluang order activity of 56% Sell / 44% Buy, BAT (Basic Attention Token) at Rp3,154 with a 1-day change of +2.47% and 34% Sell / 66% Buy activity, and KSM (Kusama) at Rp72,936 with a 1-day change of +2.41% and 0% Sell / 100% Buy activity. Typical hold times on Pluang range from 80 to 153 days for these assets.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App